IgA nephropathy is the most common form of glomerulonephritis worldwide. Renal deposits of IgA immune complexes (IgA-IC) cause injury with remarkable similarities in the pathophysiologic features of human and experimental IgA nephropathy. This suggests that common genomic expression profiles account for the similar phenotypic changes of IgA nephropathy. Despite extensive studies, there is paucity of information about an effective therapeutic modality for IgA nephropathy. The mushroom Cordyceps sinensis extracts (CSE), a traditional Chinese medicine has been reported as a potential therapy for IgA nephropathy. Our long-term goal is to elucidate the molecular mechanisms underlying the pathogenesis of IgA nephropathy as a necessary pre-requisite to the development of rational therapeutic modalities. Based on clinical and experimental observations, the specific hypothesis is that IgA-IC activate Nuclear Factor-KappaB (NF-KappaB) signalinq pathway to generate a cascade of pro-inflammatory cytokines and growth factors consummating in glomerular sclerosis, interstitial fibrosis, and renal failure. A corollary of this postulate that Cordyceps (alternative medicine) inhibition of the NF-KappaB signalinq pathway will ameliorate IgA nephropathy.
The specific aims are to: 1. Determine the influence of Cordyceps sinensis extract on NF-KappaB signaling pathway activation and ability to halt progression of renal injury in IgA nephropathy. This will be achieved by correlating the level of NF-KappaB activation in transgenic luciferase reporter model with (i) IgA-IC deposition in immune and renal tissues, (ii) induction and progression of renal injury and (iii) comparing CSE effects with known anti-inflammatory and immunosuppressive NF-KappaB modulators (Prednisolone and Cyclosporine-A). 2. Identify pivotal genes in IgA nephropathy transcriptome profiles modulated by NF-KappaB signaling and in response to CSE, Prednisolone or Cyclosporine-A. This will be achieved by (i) comprehensive transcriptome analysis, (ii) correlation of tissue luciferase activity level (NF-KappaB activation) with transcripts intensity, and (iii) expression validation of identified informative genes. These studies will generate novel insights into molecular mechanisms underlying pathogenesis of IgA nephropathy and predict outcomes from safe traditional alternative medicine for prevention of renal failure.

Agency
National Institute of Health (NIH)
Institute
National Center for Complementary & Alternative Medicine (NCCAM)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AT001465-01A2
Application #
6820657
Study Section
Special Emphasis Panel (ZAT1-DB (13))
Program Officer
Klein, Marguerite
Project Start
2004-09-15
Project End
2006-05-31
Budget Start
2004-09-15
Budget End
2005-05-31
Support Year
1
Fiscal Year
2004
Total Cost
$185,750
Indirect Cost
Name
Rhode Island Hospital
Department
Type
DUNS #
075710996
City
Providence
State
RI
Country
United States
Zip Code
02903
Gong, Rujun; Rifai, Abdalla; Ge, Yan et al. (2008) Hepatocyte growth factor suppresses proinflammatory NFkappaB activation through GSK3beta inactivation in renal tubular epithelial cells. J Biol Chem 283:7401-10
Chao, T-K; Rifai, A; Ka, S-M et al. (2006) The endogenous immune response modulates the course of IgA-immune complex mediated nephropathy. Kidney Int 70:283-97
Ka, Shuk-Man; Rifai, Abdalla; Chen, Jan-Hen et al. (2006) Glomerular crescent-related biomarkers in a murine model of chronic graft versus host disease. Nephrol Dial Transplant 21:288-98
Gong, R; Rifai, A; Dworkin, L D (2006) Hepatocyte growth factor suppresses acute renal inflammation by inhibition of endothelial E-selectin. Kidney Int 69:1166-74
Gong, Rujun; Rifai, Abdalla; Dworkin, Lance D (2005) Activation of PI3K-Akt-GSK3beta pathway mediates hepatocyte growth factor inhibition of RANTES expression in renal tubular epithelial cells. Biochem Biophys Res Commun 330:27-33